UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007182
Receipt number R000008461
Scientific Title Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria
Date of disclosure of the study information 2012/02/17
Last modified on 2012/06/20 21:56:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria

Acronym

Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria (OF trial)

Scientific Title

Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria

Scientific Title:Acronym

Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria (OF trial)

Region

Japan


Condition

Condition

Urticaria

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Compare the effect of regular dose of Olopatadine and regular dose of Fexofenadine on histamine iontophoresis induced urticaria

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

Wheal area

Key secondary outcomes

Flare area, VAS for itching


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Placebo

Interventions/Control_2

Olopatadine 5mg

Interventions/Control_3

Fexofenadine 60mg

Interventions/Control_4

Fexofenadine 120mg

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

45 years-old >

Gender

Male and Female

Key inclusion criteria

1. Participants should consent to this trial with written agreement form.
2. Male and female
3. From 20 years old to 44 years old
4. From 50 kg to 85 kg in body weight
5. From 18.5 to 25.0 in body mass index
6. Nonsmoker

Key exclusion criteria

1. Participate in other trial within 120 days.
2. Taking some medicine
3. History of drug allergy
4. History of sever skin disease
5. History of liver disease
6. History of heart disease
7. History of respiratory disease
8. History of digestive disease
9. History of kidney or cerebrovascular disease
10. History of malignancy
11. Low responder to histamine iontophoresis
12. Heavy drinker
13. Participant who judged as inadequate for this trial

Target sample size

12


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Fujio OTSUKA

Organization

University of Tsukuba

Division name

Department of Dermatology, Faculty of Medicine

Zip code


Address

1-1-1, Ten-nohdai, Tsukuba, Ibaraki, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Jun-ichi FURUTA

Organization

University of Tsukuba

Division name

Department of Dermatology, Faculty of Medicine

Zip code


Address

1-1-1, Ten-nohdai, Tsukuba, Ibaraki, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

Faculty of Medicine, University of Tsukuba

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

株式会社SOUKEN 臨床試験室(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 01 Month 23 Day

Date of IRB


Anticipated trial start date

2012 Year 02 Month 01 Day

Last follow-up date

2012 Year 03 Month 01 Day

Date of closure to data entry

2012 Year 04 Month 01 Day

Date trial data considered complete

2012 Year 04 Month 01 Day

Date analysis concluded

2012 Year 04 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 01 Month 31 Day

Last modified on

2012 Year 06 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008461


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name